Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

49.81
+0.29000.59%
Volume:326.59K
Turnover:16.16M
Market Cap:3.93B
PE:-10.54
High:49.85
Open:49.27
Low:48.45
Close:49.52
Loading ...

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Zacks
·
Yesterday

PTC Therapeutics Inc : Leerink Partners Raises Target Price to $52 From $50

THOMSON REUTERS
·
Yesterday

Rpt-Ema Says Chmp Recommended Granting Conditional Marketing Authorisation for Ziihera (Zanidatamab)

THOMSON REUTERS
·
25 Apr

BRIEF-EMA Says Tepezza Received Positive CHMP Opinion For Treatment Of Adults With Moderate To Severe Thyroid Eye Disease

Reuters
·
25 Apr

Rpt-Ema Says Sephience (Sepiapterin) Got Positive Opinion From Chmp for Treatment of Hyperphenylalaninaemia in Adults & Children With Phenylketonuria

THOMSON REUTERS
·
25 Apr

Corrected-Ema Says Chmp Will Re-Examine (Not 'Requested Re-Examination of') Opinion Adopted for Marketing Authorisation Holder for Kisunla (Donanemab)

THOMSON REUTERS
·
25 Apr

Rpt-Ema Says Chmp Recommends Conditional Marketing Authorisation for Duvyzat (Givinostat), as Treatment for Dmd in Patients From Age Six Who Can Walk

THOMSON REUTERS
·
25 Apr

Ema Says Sephience (Sepiapterin) Got Positive Opinion From Chmp for Treatment of Hyperphenylalaninaemia in Adults & Children With Phenylketonuria

THOMSON REUTERS
·
25 Apr

PTC Therapeutics Says Potential Phenylketonuria Drug Receives EU Panel's Positive Opinion

MT Newswires Live
·
25 Apr

BRIEF-PTC Therapeutics Receives Positive CHMP Opinion For Sephience™ (Sepiapterin) For The Treatment Of Children And Adults Living With Phenylketonuria (PKU)

Reuters
·
25 Apr

PTC Therapeutics Inc - European Commission Expected to Ratify Sephience Authorization in Two Months

THOMSON REUTERS
·
25 Apr

PTC Therapeutics Receives Positive Chmp Opinion for Sephience™ (Sepiapterin) for the Treatment of Children and Adults Living With Phenylketonuria (Pku)

THOMSON REUTERS
·
25 Apr

PTC Therapeutics Inc: European Launch Preparations Underway

THOMSON REUTERS
·
25 Apr

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

PR Newswire
·
25 Apr

PTC Therapeutics CEO Makes Significant Stock Move

TIPRANKS
·
25 Apr

PTC Therapeutics Price Target Maintained With a $65.00/Share by RBC Capital

Dow Jones
·
22 Apr

PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?

Zacks
·
17 Apr

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

PR Newswire
·
17 Apr

Top Executive Sells Hundreds of PTC Therapeutics Shares!

TIPRANKS
·
05 Apr

RBC Lifts Price Target on PTC Therapeutics to $65 From $64, Keeps Outperform Rating

MT Newswires Live
·
03 Apr